These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23303027)

  • 1. The study of p53 and p16 immunoexpression in serous borderline and malignant ovarian tumors.
    Marinaş MC; Mogoş DG; Simionescu CE; Stepan A; Tănase F
    Rom J Morphol Embryol; 2012; 53(4):1021-5. PubMed ID: 23303027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
    Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
    Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
    Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
    Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.
    Bilyk OO; Pande NT; Buchynska LG
    Exp Oncol; 2011 Sep; 33(3):150-6. PubMed ID: 21956468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
    Wen J; Shi JL; Shen DH; Chen YX; Song QJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
    Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
    J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of p16, p53, CD24, EpCAM and calretinin in serous borderline tumors of the ovary.
    Aktaş IY; Buğdayci M; Usubütün A
    Turk Patoloji Derg; 2012; 28(3):220-30. PubMed ID: 23011824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma.
    Phillips V; Kelly P; McCluggage WG
    Int J Gynecol Pathol; 2009 Mar; 28(2):179-86. PubMed ID: 19188815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
    Giurgea LN; Ungureanu C; Mihailovici MS
    Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.
    Novak M; Lester J; Karst AM; Parkash V; Hirsch MS; Crum CP; Karlan BY; Drapkin R
    Gynecol Oncol; 2015 Oct; 139(1):104-11. PubMed ID: 26206555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p16 in serous ovarian neoplasms.
    Nazlioglu HO; Ercan I; Bilgin T; Ozuysal S
    Eur J Gynaecol Oncol; 2010; 31(3):312-4. PubMed ID: 21077476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 and Ki67 immunoexpression in mucinous malignant ovarian tumors.
    Kamal CK; Simionescu CE; Mărgăritescu C; Stepan A
    Rom J Morphol Embryol; 2012; 53(3 Suppl):799-803. PubMed ID: 23188443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
    Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
    Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
    O'Neill CJ; McBride HA; Connolly LE; Deavers MT; Malpica A; McCluggage WG
    Histopathology; 2007 May; 50(6):773-9. PubMed ID: 17493241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
    Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
    Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequency and prognostic role of P53 and P16 immunoexpression in primary ovarian mucinous tumors.
    Nergiz D; Yıldırım HT; Süren D; Sadullahoğlu C; Yıldırım Ş; Üreyen I
    Ann Diagn Pathol; 2024 Oct; 72():152330. PubMed ID: 38772285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.